Chethan Ramamurthy

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors

Julia Judd, Matthew R. Zibelman, Elizabeth A. Handorf et al. · The Oncologist · 2017 · 133 citations · Full text

Medicine, Immunology, Oncology +17

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

Petros Grivas, Damien Pouessel, Chandler H. Park et al. · Journal of Clinical Oncology · 2024 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17

Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer

Chethan Ramamurthy, Elizabeth A. Handorf, Andres Correa et al. · Urologic Oncology Seminars and Original Investigations · 2019 · 38 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

Jonathan E. Rosenberg, M. Milowsky, Chethan Ramamurthy et al. · Annals of Oncology · 2022 · 38 citations

Medicine, Oncology, Pharmacology +9